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Abstract 
Psoriatic arthritis (PsA) is a heterogeneous inflammatory arthritis with a varied 
clinical phenotype. There has been considerable international collaboration 
over recent years to develop and prioritise appropriate disease domains and 
outcome measures to capture all aspects of this complex disease. It has been 
recognised that patient reported measures and physician assessments are 
complementary and when used together allow an improved reflection of 
disease burden. Taking this concept one step further the experience in 
rheumatoid arthritis has demonstrated benefits of incorporating the patient 
perspective in the development of outcome measures. We report a systematic 
review demonstrating there has been little incorporation of the patient 
perspective in the development of outcome measures and domains in PsA, 
the proceedings from the preliminary patient involvement in outcome 
measures for PsA (PIOMPSA) meetings and a proposed roadmap for 
improving patient involvement. 
 
  
Introduction 
 
Psoriatic arthritis (PsA) is a complex disease with a varied clinical phenotype 
affecting the skin, joints, nails, entheses and axial skeleton. Historically 
disease outcome has been measured with tools adapted from related 
inflammatory diseases such as rheumatoid arthritis (RA) and axial 
spondyloarthritis.1 It became apparent that such borrowed instruments did not 
capture all aspects of this multifaceted disease and considerable progress 
has been made in the development of disease domains and composite 
measures for PsA in recent years. The Group for Research and Assessment 
of Psoriasis and Psoriatic Arthritis (GRAPPA) in collaboration with Outcome 
Measures in Rheumatology (OMERACT) have been actively involved with this 
process, defining appropriate domains of assessment and tools to measure 
them.2, 3  
 
An obvious way of capturing all components of PsA has been an expansion in 
the use of patient reported outcome (PRO) measures assessing health 
related quality of life, physical function, work, pain, fatigue and global health.1, 
4 The use of PRO’s arose from the realisation that the patient perspective 
brings a unique insight into the measurement of disease activity that was 
previously not captured by traditional, physician-centric outcome measures 
such as clinical examination and biomarkers. Moreover incorporating PRO’s 
has the potential of reducing the impact of the known discordance in disease 
assessment between physician and patient, as demonstrated in RA5, 6 and 
PsA7. There is consensus that both PRO’s and physician assessed measures 
are required to effectively capture all aspects of disease and that this 
combined approach results in a truer reflection of disease and thus both are 
incorporated in the OMERACT core set for PsA.8 
 
In recent years we have seen the PRO’s concept extended to the 
incorporation of the patient perspective in the OMERACT process.9 Patients 
have brought a new perspective to how domains of disease should be 
prioritised and measured, thus enhancing the ‘truth’ aspect of the OMERACT 
filter.10, 11 The European League Against Rheumatism (EULAR) has also 
recognised this issue and recommends the inclusion of the patient 
perspective in scientific projects.12, 13 Furthermore the National Institute of 
Health Research (NIHR) in the United Kingdom has convened the INVOLVE 
group to promote patient involvement in all aspects of the NHS including 
research. Despite the growing recognition of the benefits of incorporating the 
patient perspective it has recently become apparent that there has been little 
patient involvement in the development of PsA domains and outcome 
measures. We report a systematic review of patient involvement in the 
development of outcome measures and domains in PsA, the proceedings 
from the preliminary GRAPPA special interest group for Patient Involvement 
in Outcome Measures for PsA (PIOMPSA) meetings and a proposed action 
plan for improving patient involvement.  
  
Systematic review of patient involvement in PsA 
We set out to establish the degree of patient involvement during the 
development of the original domain construct, outcome measure and disease 
activity indices used in psoriatic arthritis.  
 
Methods 
A literature search was performed of Medline and Embase (1970- present) 
and the Cochrane database on January 3rd 2013. Publications were identified 
using the following keyword or MeSH terms: “psoriatic arthritis” in combination 
with (AND) “Domain” OR “Outcome” OR “Assessment” OR “Validation” (AND) 
“Composite measure”, “physical function”, “skin activity”, “patient global”, 
“pain”, “health related quality of life”, “peripheral joint activity”, “enthesitis”, 
“dactylitis”, “fatigue”, “nails”, “physician global”, “spinal”, “participation” as 
listed in the OMERACT core set for PsA. Radiology, MRI, USS, CT, tissue 
analysis and acute phase reactants were not included in the search. The 
following limitations were applied; “Humans”, “English Language”, “published 
1970 to present”.  
 
Inclusion criteria: Any study developing an outcome measure or core set of 
outcome measures for use in PsA. Exclusion criteria: Review articles, 
conference abstracts, articles not reporting data specific to PsA, articles not 
reporting any clinical outcomes (such as genetic, radiographic or laboratory 
measures), articles not developing an outcome measure for use in PsA. Data 
extraction; Abstracts were screened for the presence of exclusion criteria and 
the remaining articles were subject to full text review. A ‘pearl growing’ 
approach was then employed. For each outcome measure found the first 
article validating or using an outcome measure in PsA was selected along 
with any citing articles (citation tracking) and their references (reference 
tracking). This approach was felt to be the most effective and efficient way of 
identifying the literature. Articles were screened and reviewed for using a 
literature evaluation tool. The tool was developed through consensus by the 
authors based upon the INVOLVE and EULAR guidelines for patient 
involvement in research.12, 14 The level and type of patient involvement was 
recorded; patient selection (for communication skills, motivation, constructive 
assertiveness), training (background information), consultation (patients 
consulted on their views through interview or focus groups), collaboration (on-
going relationship such with the research team or advisory board), whether 
the research was user-led (patient directed and managed research) and 
finally recognition of the patient involvement.  
 
Results 
The search results are reported in Figure 1: 1238 articles were identified for 
abstract review. Twenty-six articles were selected as ‘pearls’. Two hundred 
and eight further articles were identified during the citation search and sixty 
three from the reference search. Two hundred and thirty four articles were 
excluded as duplicates, review articles, not related to PsA and not related to 
the development of an outcome measure. Thus, sixty three articles were 
selected for final inclusion, summarised in Table 1.  
 
Six articles described some patient involvement. Only one outcome measure, 
the Psoriatic Arthritis Quality of Life (PsAQoL), described patient involvement 
during the initial development stage.15 In this study the patients involvement 
was proportional and acknowledged but there was no evidence of patient 
selection, training or on-going collaboration in the tools refinement. Two 
further studies involved patients in the assessment (but not development of) 
existing measures.16, 17  
 
Three articles reported the involvement of four patients during the 
development of the OMERACT core set for PsA. There were no patients at 
the first OMERACT 7 workshop where PsA domains were first discussed. 
Deliberations were based on two previous GRAPPA exercises to identify 
domains, a Delphi process3 and a nominal group process8. The Delphi 
processes included thirty two rheumatologists and no patients. The group 
process included three groups reported to contain representatives from 
rheumatology, dermatology, patients and industry sponsors (without a vote) 
but exact numbers were not reported or available from records. As a result of 
these deliberations, a set of domains was identified. This data was reviewed 
in the OMERACT 7 workshop before participants were divided into twelve 
groups to discuss domains that should be included in PsA clinical trials. 
Domains suggested were then voted on and summarised into a summary 
table and presented at a plenary session. The final consensus on a core set 
of domains was made at OMERACT 8. One patient of four with PsA 
presented a personal story of living with PsA at this meeting amongst 137 
physicians. After a plenary session at which current status of measures used 
to assess PsA were reviewed, and discussion at breakout groups, the group 
achieved consensus on six domains for the inner circle of the core set. 
 
In summary this systematic review establishes that much of the original 
domain construct, outcome measure, disease activity and responder indices 
were developed and prioritised without substantial incorporation of the patient 
perspective. 
 
PIOMPSA Special Interest Group 
The PIOMPSA Special Interest Group (SIG) was formed as part of a 
GRAPPA initiative to address the historic lack of patient involvement in the 
development of PsA outcome measures. The group brings together seven 
rheumatologists (AA, LC, OF, LG, PH, NJM and WT) one professor of 
rheumatology nursing (SH), one nurse practitioner (PM) and six 
representatives of the patient perspective (MB, WC, JJ, AR, DO’S and 
MdeW). The group had representatives from the UK, Ireland, Canada, France 
and the Netherlands.  
 
Proceedings of the first PIOMPSA meeting 
 
The first step was an initial meeting held in Dublin in August 2012. The aim of 
this meeting was to agree on a preliminary roadmap for involving the patient 
perspective in the further development of outcome measures and domains of 
PsA, with a view of incorporating this in an OMERACT 14 workshop proposal. 
To this end a meeting was convened and introductory presentations were 
made to facilitate group discussion. 
 
Introductory presentations 
MdeW reviewed the role of patients in research, describing the opportunities 
for patient involvement at each step of the research process from design 
through to implementation and reporting. The EULAR recommendations 
clarify how this may be achieved including the roles patients may take, 
numbers, recruitment, selection, support, training and acknowledgment.12 
NJM reviewed the OMERACT core set of domains and the tools to measure 
them in PsA studies.2 He highlighted the importance of PRO’s as a reliable, 
patient centred, feasible and sustainable method of data collection in 
longitudinal observational studies. The importance of physician measures 
such as the joint count and skin score were also recognised but that they 
require relatively high levels of training. NJM indicated that the level of patient 
participation in the development of any existing measures or domains was 
likely to have been minimal and that there was a need for this to be 
established with a systematic review. PH discussed the role of composite 
measures as a method of capturing all aspects of disease activity in PsA. 
There is a lack of consensus currently on the three novel measures: the 
Composite Psoriatic Disease Activity Index (CPDAI), the Arithmetic Means of 
Desirability Functions (AMDF) and the Psoriatic Arthritis Disease Activity 
Score (PASDAS). Again it was felt likely there had been minimal patient 
involvement in the development of these scores. PM discussed the 
importance of fatigue as an outcome measure in RA and PsA but 
acknowledged there was a current lack of a validated tool to use in PsA and 
that further research was required. Two studies developing novel instruments 
currently underway are incorporating the patient perspective; the Psoriatic 
Arthritis Impact of Disease (PsAID) study18 and the disease flare initiative. 
 
Group discussions 
Whilst it was recognised that all domains are important on an individual basis 
some may not be sufficiently responsive to change to warrant inclusion in an 
activity measure. Conversely domains that are subject to little variation may 
not be suitable as response measures and better incorporated ‘impact’ or 
severity measures. There was a feeling amongst the group that despite these 
variances all items should be tracked as part of the research agenda.  
 
There was recognition that some aspects of disease important to patients are 
not currently included in the existing composite measures (fatigue, pain, work, 
participation) and it was agreed that the patient perspective was essential in 
justifying the inclusion and exclusion of individual items. The patient 
participants wondered what rationales are behind the novel composite 
measures and why these scores do not include all OMERACT PsA core 
domains. The group summarised with the following agreements and action 
plan: 
 There was a need to definitively confirm the level of patient 
involvement in outcome measure and domain development with a 
systematic review. 
 In order to inform a roadmap to improve future patient involvement the 
group should meet again to review;  
o The OMERACT experience of incorporating the patient 
perspective in choosing and developing instruments in RA.  
o The findings of the systematic review. 
o The preliminary findings of the PsAID project and Flare studies  
 
Proceedings of the Bath follow up meeting 
 
The meeting took the following structure; MdeW prepared pre-meeting 
reading material for all members of the group covering the project 
background, concepts of outcome measurement, OMERACT and its process 
and a glossary of terminology, introductory presentations were made to inform 
discussions and concluded in a summary action plan. 
 
Introductory presentations 
OF reviewed the Dublin meeting outcomes and the group discussed the 
opportunity of raising the issue of improved patient participation at GRAPPA 
through a workshop at the forthcoming Toronto meeting. AA drew the groups’ 
attention to INVOLVE, a UK based body promoting patient involvement in the 
NHS and particularly research.14 This national profile for patient involvement 
was further support for the PIOMPSA groups’ objectives.  
 
MdeW presented a patients perspective of ten years involvement with 
OMERACT. He outlined the need to understand the impact of disease through 
the patient perspective before selecting domains, a core set, tools for 
measurement and cut off values for treatment response. Layered into this 
process he described the historic discrepancies between the physician and 
patient perspectives of disease activity. Fatigue was used as an example of 
an outcome important to patients, but not included in the existing inner circle 
of the OMERACT core set that was selected and prioritised by physicians. 
Finally he drew attention to the poor reporting of the core set and the 
importance that all domains are reported with none left out, as recently 
systematically reviewed by Palominos et al.4 Discussions ensued on the 
importance of individual domains, the historic omission of fatigue and the on-
going development of the Bristol Rheumatoid Arthritis Fatigue (BRAF) scale.  
 
AA raised the potential issue of how disagreement between physicians and 
patients in prioritising domains for core-sets or composite measures would be 
addressed. LC used the RA flare group experience to describe a method of 
avoiding conflict and achieving agreement through a Delphi process of 
ranking and consensus to incorporate all perspectives.  
 
PH presented the preliminary findings from the PsAID18 and Flare studies 
(unreported findings). The EULAR PsAID initiative was conceived from the 
belief that the patient perspective is not fully reflected in existing tools and has 
the aim of addressing this through appropriate involvement during the 
development of a new disease impact measure, the PsAID. The group is 
made up of patients, rheumatologists, dermatologists and allied health 
professionals from 13 countries. He went on to describe the study starting 
with the identification and selection of sixteen domains identified by patients at 
the first meeting. The domains were then prioritised by a ranking exercise 
including more than 130 patients. After excluding four domains with low sores 
in the ranking exercise two weighting systems were employed to create two 
versions, one for nine domains and one for twelve. A longitudinal study of 
>400 patients in thirteen countries found the feasibility, reliability and 
sensitivity of the two tools to be good.18 
 
PH then went on to discuss the Flare study. Flare is a very different 
experience for every patient and there is a need for a standardised definition. 
SH led on an international qualitative study that identified the core elements of 
RA flare, which prompted discussion from the patient representatives in the 
group on the experience of flare.19 The local Bath PsA group (named PsAZZ) 
meet to exchange views and flare had recently been discussed. The group 
emphasised the importance of two particular aspects of flare; the systemic 
feelings of ill health found in flare dubbed the ‘yuk factor’ and ability to work.  
 
WT presented the findings of the systematic literature review. The group went 
on to discuss how the patient perspective may influence the existing domain 
selection and outcome measures. 
 
Group discussion on the OMERACT core set of PsA domains 
The group posed the question that in light of the findings of the very low levels 
of patient involvement identified in the systematic review was it necessary to 
review the core domains and the tools to measure them? Were there domains 
that were not included in the inner circle that perhaps should be, such as 
dactylitis and fatigue?2 It was noted that there was little difference in the 
scores at OMERACT 8 between those domains finally included in the inner 
circle and those not.2 Originally only domains with validated measures were 
included in the inner circle leaving those without to the outer circle or research 
agenda. The group discussed the examples of fatigue and dactylitis.  
 
The domain of fatigue had caused much debate at the OMERACT workshops 
but was finally placed in the outer circle because there was no agreed 
instrument to measure it. Since OMERACT 8 there has been considerable 
work in the development of many outcomes in PsA which may influence the 
ranking of domains.2 The patients in the group commented that although 
fatigue had been identified as an important outcome from the patient 
perspective, and despite the fact that a validated instrument was lacking, no 
research was initiated at that stage to develop a measure of fatigue in PsA. 
Moreover the evidence that will be reported in the PsAID study suggests 
fatigue ranks third of sixteen domains behind pain and skin disease from the 
patient perspective indicating its place in the core set may need to be 
reconsidered. However, a validated instrument to measure fatigue in PsA is 
still lacking.  
 
The group felt that it was important to reconsider the place of dactylitis in the 
core set, currently in the outer circle. It was suggested that the measurement 
of dactylitis is covered through within the existing joint count or within the 
assessment of physical function, both included in the inner circle, and as such 
separate measurement was not required. An alternate view point voiced by 
the group was that dactylitis is a characteristic and frequent manifestation of 
PsA rarely seen in other diseases so specific measurement is warranted. 
Additionally there is a validated measure available in the Leeds Dactylitis 
Index (LDI) for its measurement.20  
 
The group then posed the question; should domain selection be based on 
areas affecting ‘a significant proportion’ of patients as in the RA model? Whilst 
this seems reasonable to include domains affecting a significant proportion of 
patients there was agreement that this approach was flawed in PsA. The 
variable clinical phenotype may mean such an approach would miss disease 
activity amongst those affected in less common domains. Furthermore if 
treatment decisions are being made on the basis of core set outcome 
measures the domains included become critically important.  
 
In summary there was a feeling that all important domains should be included 
in the core set thereby forcing the development of appropriate measures and 
that this proposal should be taken forward for discussion at the GRAPPA 
Toronto Workshop.  
 
Outcome measurement 
There are many measures now available for the measurement of domains in 
the inner circle of the OMERACT core set but a lack of consensus on which 
were most discriminatory. The advantages and limitations of the currently 
available measures, including the novel composite indices were outlined by 
physicians within the group. By example the advantages of composite 
measures were outlined, including; the ability to capture multiple domains, 
better quantification of the total burden of disease in someone with low activity 
but in multiple domains and their sensitivity to change enabling smaller, less 
expensive and quicker studies. Limitations include factors such as; they are 
often time consuming to complete, require training and have the potential of 
masking fluctuation in a single disease area by other domains. PH introduced 
the idea that the arithmetically derived AMDF could be adapted to incorporate 
different domains to reflect changes in the inner circle of the core set then be 
re-validated. The group proposed that there may be a need for a minimal 
‘inner circle’ composite index and a second ‘expanded’ composite to 
incorporate broader domains. The possibility of revising the CPDAI, with 
patient involvement, was also discussed including the possibility of expanding 
the index to include a patient global score.  
 
The group discussed the lack of objective evidence that incorporating the 
patient perspective improves outcome measures. Such a study would be very 
difficult to design and taken with the theoretical advantages is arguably not 
required. Perhaps the first argument is that incorporating the patient 
perspective ensures that PsA outcomes research remains patient centred. An 
example of the success of this approach may be found in the improved profile 
and measurement of fatigue in RA.13 Furthermore there are advantages on 
individual and group/ association level whereby patients may feel a greater 
sense of empowerment through more involvement with research.21 Such 
relationships may bring additional advantages such as improved participation 
in future research projects and the implementation of research findings.  
 The group acknowledged difficulties in incorporating the patient perspective.12 
In summary these include, but are not limited to; overcoming the asymmetrical 
nature of the physician/ patient relationship and the importance of creating a 
supportive and equal partnership; achieving ‘representativeness’ of the patient 
perspective through appropriate selection of patients and finally avoidance of 
relying solely on long term patient partners who may become professional 
with time thereby bring another medical opinion rather than the true patient 
perspective.  
 
Conclusion 
We report a systematic review of patient involvement in the development of 
outcome measures and domains in PsA together with the proceedings of the 
first meetings of the PIOMPSA group. We have outlined the background and 
aims of this special interest group together with discussion around the 
potential advantages and difficulties of incorporating the patient perspective in 
developing instruments for measuring disease outcome. These group 
discussions have identified research topics around domain selection and 
outcome measurement where the patient perspective may influence future 
research. The group concluded with agreement on the following action points; 
 There is a historic underrepresentation of the patient perspective in the 
development of PsA domain selection and outcome measures, 
demonstrated in this systematic review and discussions. 
 Ideas introduced in the PIOPMSA meetings could be refined in a 
GRAPPA special interest group with voting on a roadmap for achieving 
meaningful incorporation of the patient perspective in future research. 
 There is a case for reviewing the OMERACT PsA core set with 
meaningful patient representation. 
 The AMDF or CPDAI could be revised to incorporate domains included 
in the inner circle.  
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Table 1: Systematic literature review of PsA outcome measures by domain 
Core set Domain Outcome Primary article (number of 
Pubmed citations) 
Articles included from the 
Citation/ Reference search 
Inner circle Physical function HAQ Blackmore 1995 (11)22 Pincus 199923 
Husted  1995/ 2001/5/724-27 
Leung 200828 
Brodsky 201029 
Mease- 201130 
Kwok201031 
Wolfe 200432 
MacKenzie 201117 
Daltroy 199033 
Stamm 200716 
  SF36 Husted 1997(11)34 Stamm 200716 
Taylor 200735 
Husted 200124 
Leung 2010/ 0828, 36 
Kvamme 200937 
MacKenzie 201117 
Shikiar 200338 
  AIMS Husted 1996 (5)39 Husted 199640 
Duffy 199241 
Stamm 200716 
 Health related 
Quality of Life 
EQ5D Sokoll 2001 (22)42 
 
Brodsky 201029 
Singh 200943 
Kvamme 200937 
MacKenzie 201117 
Shikiar 200338 
  PsAQol McKenna 2004 (9)15 Stamm 200716 
Brodsky 201029 
Healy 200844 
Billing 2010 
  DLQI  
 
Nicol 1996 (4)45 Stamm 200716  
MacKenzie 201117 
Shikiar 200338 
  ASQUol Nil in PsA  
     
 Patient global Patient global 
VAS/ Numeric 
Cauli 2011 (0)46 Kwok 201031 
Leung 201247 
Dandorfer 20127 
 Peripheral joint 
activity 
Joint count Gladman 2007 (5)48 Nil 
 Skin activity PASI Fredriksson 1974(64)49 Louden 200450 
Feldman 199651 
Shikiar 200338 
Carlin 200452 
 Pain Pain VAS Kwok 2010 (1)31 Nil 
Outer circle Physician global PGA Nil in PsA Nil 
 Fatigue BASFI Leung 2008 (2)28 MacKenzie 201117 
  FACIT-fatigue Chandran 2007 (4) Nil 
 Enthesitis LEI Healy 2008- (3)53 Nil 
  MASES Gladman 2007 (5)48 Nil 
  SPARCC Maksymowych 2009 (3)54 Gladman 200755 
 Dactylitis LDI Heliwell 2005 (1)56 Healy 2000720 
Gladman 200748 
 Spinal BASMI Gladman 2007 (3)55 Leung 201157 
Fernandez-Sueiro 200958 
  BASDAI Taylor 2004 (2)59 Stamm 200716 
Leung 200828 
Fernandez-sueiro 201060  
Eder 201061 
MacKenzie 201117  
 Nails NAPSI/ mNAPSI Rich 2003 nil (4)62 Aktan 200763 
Cassell 200764 
Maejima 201065 
Research 
agenda 
Participation    
OMERACT 
core set 
Core domains  Gladman 2007 (4)2 Taylor 20053 
Gladman 20058 
Gladman 200566 
Composite 
measures 
Composite 
measures 
CPDAI Mumtaz 2011 (0)67 Fitzgerald201268 
  DAPSA/ DAREA Nell-Duxneuner 2010 (169) Schoels 2010 (1)70 
  MDA Coates 2010 (0)71 Coates 2010 72 
Coates 2010 73 
  PsAJAI Gladman 2010- 1892-7 (1)74 Gladman 201075 
Nell-duxneuner 201069 
  PASDAS & AMDF Helliwell 2012 (0)76 Nil 
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